Cargando…
Heterogeneity of the resistance to gefitinib treatment in a non‐small cell lung cancer patient with active epidermal growth factor receptor mutation
We report the case of a 37‐year‐old male non‐small cell lung cancer patient with an active epidermal growth factor receptor (EGFR) mutation who received gefitinib as first‐line treatment. After 13.7 months, the patient experienced disease progression and was treated with platinum‐based doublet chemo...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217905/ https://www.ncbi.nlm.nih.gov/pubmed/27801981 http://dx.doi.org/10.1111/1759-7714.12382 |